Overview

A Study Of Pembrolizumab In Combination With Trastuzumab-DM1

Status:
Active, not recruiting
Trial end date:
2025-01-01
Target enrollment:
Participant gender:
Summary
This research study is studying a combination of drugs as a possible treatment for metastatic breast cancer. The interventions involved in this study are: - Pembrolizumab - Trastuzumab emtansine (also called T-DM1)
Phase:
Phase 1
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Ado-Trastuzumab Emtansine
Maytansine
Pembrolizumab
Trastuzumab